Condition: Non-Small Cell Lung Cancer · Sponsor: RemeGen Co., Ltd.
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
This description comes directly from the study's public registry record.
Heping Liu · +86-010-65384976 · heping.liu@remegen.com
Always discuss trial participation with your own doctor first.
| Beijing Chest Hospital,Capital Medical Unniversity | Beijing, China | Recruiting |
| The Fifth Medical Center of Chinese People's Liberation Army General Hospital | Beijing, China | Recruiting |
| Binzhou Medical University Hospital | Binzhou, China | Recruiting |
| Jilin Cancer Hospital | Changchun, China | Recruiting |
| The Second Xiangya Hospital Of Central South University | Changsha, China | Recruiting |
| Changzhou Cancer Hospital | Changzhou, China | Recruiting |
| Sichuan Cancer Hospital | Chengdu, China | Recruiting |
| West China hospitial of SiChuan University | Chengdu, China | Recruiting |
| Chongqing University Cancer Hospitai | Chongqing, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| Ganzhou cancer Hospitial | Ganzhou, China | Recruiting |
| Affiliated Cancer Hospital of Guangzhou Medical University | Guangzhou, China | Recruiting |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06962865